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Rhabdomyosarcoma (RMS) is a pediatric cancer of skeletal muscle that is thought to occur because 
of a failure of myoblasts to fully differentiate. The DNA binding protein MyoD drives the differentiation 
of myoblasts into terminally differentiated myotubes; however, it is expressed normally in RMS cells. 
It is therefore unclear why RMS cells remain immature. In a study published in Molecular and 
Cellular Biology, graduate student Kyle L. MacQuarrie (Human Biology Division) and Dr. Stephen J. 
Tapscott (Human Biology and Clinical Research Divisions) use a genome-wide approach to identify 
differences in MyoD binding between RMS and normal muscle and epigenetic differences that may 
influence myotube differentiation. 
MyoD is a basic helix-loop-helix (bHLH) transcription factor, which heterodimerizes with E-protein to 
transactivate gene expression and promote muscle cell differentiation. Previous studies in mice 
demonstrated that MyoD binding sites are ubiquitous across the genome in both myogenic stem 
cells and differentiated myotubes, often near potential binding sites for other myogenic factors such 
as Runx and Sp1. Furthermore, gene expression during differentiation is positively correlated with 
the level of MyoD binding near a given gene. These observations led the team to ask whether or not 
MyoD binds DNA differently in RMS than in normal cells. 
To answer this question, the team performed ChIP-seq analysis for MyoD in primary human 
myoblasts and myotubes, as well as RD cells, a model for RMS. The team found that 30-60,000 
sites were occupied by MyoD across the genome of both human myoblasts and myotubes. 50-90% 
of these sites are occupied by MyoD in both cell types, and gene expression was positively 
correlated with the level of MyoD binding. Surprisingly, most of these MyoD binding sites were also 
occupied in RD cells. However, the team did find two types of differences; regional differences, in 
which areas >100 kb had consistently higher or lower MyoD binding profiles, and local differences, in 
which an individual binding site, but not neighboring sites, displayed differential binding profiles. 
ENCODE project data showed that myoblast genomic regions which bind lower levels of MyoD than 
RD cells are also less susceptible to DNase I at these sites. This observation suggested that 
chromatin accessibility may influence MyoD binding in these regions. Supporting this hypothesis, 
team found that RD cell PvuII cleavage sites in regions with reduced MyoD binding were less 
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susceptible to digestion relative to the same region in normal myoblasts with a stronger MyoD 
binding signature.  
A motif analysis of sequences adjacent to MyoD sites differentially bound in myotubes and RD cells 
found enrichment of RUNX1 and AP-1 binding sites, which are sufficient to drive differentiation of RD 
cells, NFIC sites, which bind bHLH co-factors in myogenic cells, and MEF2 sites which bind MyoD at 
muscle-specific promoters. When the authors overexpressed MEF, they observed increased MyoD 
recruitment to MEF2C sites. RT-PCR and expression analysis confirmed that RD cells expressed 
fewer transcripts of these myogenic cofactors than primary myotubes, suggesting that 
underexpression of these transcripts may contribute to the differentiation block in RD cells. The 
Tapscott lab found that ovrexpression of the AP-1 family member JDP2, or NFIC led to cell cycle 
withdrawal and increased expression of the MEF2C transcription factor, while overexpression of 
MEF2C alone led to increased differentiation of RD cells into myotubes. 
Taken together, these data indicate that epigenetic changes in RMS cells result in decreased 
expression of some MyoD co-factors and their regulated genes. Overexpressing these co-factors 
rescued muscle differentiation in RD cells, supporting the hypothesis that RMS is a failure of 
myoblasts to reach the threshold concentration of myogenic factors necessary to induce 
differentiation. Furthermore, this work suggests that if this threshold is crossed, normal myogenic 
differentiation may proceed in RMS cells. “The fact that multiple factors can be utilized to cause cell 
cycle withdrawal and myogenic differentiation in the tumors - due to the tightly regulated nature of 
the control of myogenic differentiation - is encouraging for the ability to find one or more drug-able 
targets,” said Kyle L. MacQuarrie. 
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Position weight matrix (PWM) of the MEF2C binding motif - a 
higher PWM indicates a potential MEF2C binding site that 
looks more 'perfect' than a site with a lower PWM score. 
Genes that are expressed more strongly and associated with 
more MyoD binding in myotubes compared to RD cells (pink) 
have a stronger association with canonical MEF2C binding 
motifs (MEF2C PWM) than those genes that have comparable 
expression and MyoD binding between myotubes and RD 
cells (blue) 
 
